Two Syncona-backed players join forces to take on retinal gene therapies
With ambitions to build an eye gene-therapy powerhouse, UK-based Gyroscope Therapeutics is swallowing US-based device maker Orbit Biomedical, which is focused on sub-retinal surgical delivery technology.
The combination of the two Syncona-backed players — which will operate under the Gyroscope name — will be led by former Genentech executive Khurem Farooq, who was responsible for managing the commercial activities of Lucentis and involved in the pre-launch work for lampalizumab at the Roche company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.